(redirected from DPP-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: deterrent
References in periodicals archive ?
6]) They are very much short acting as they are rapidly degraded by an enzyme dipeptidyl peptidase (DPP)-4 which exists in various cell types including vascular, intestinal, and renal cells, ([7]) and its inhibition by DPP-4 inhibitors prolongs the action of them.
Sitagliptin is the most widely used DPP-4 inhibitor in the UK"it was the first to market and is on most formularies.
DISCUSSION: DPP-4 inhibitors (Sitagliptin) could be used as initial therapy as they have glucosedependent [beta]-cell sensitizer activity.
Exenatide (Byetta[R]) GLP-1 Agonist Approved Onee Weekly Exenatide GLP-1 Agonist Investigational Liraglutide (Victoza[R]) GLP-1 Agonist Phase 3 Trials Sitagliptin (Januvia[R]) DPP-4 Inhibitor Approved Vildagliptin (Galvus[R]) DPP-4 Inhibitor Investigational (approved in Europe) Alogliptin DPP-4 Inhibitor Phase 3 Trials Saxagliptin (Onglyza[R]) DPP-4 Inhibitor Approved Dapagliflozin SGLT2 Inhibitor Phase 3 Trials Aleglitazar Dual PPAR/Agonist Phase 2 Trials
Both of the DPP-4 inhibitors will be reviewed for approval by the Food and Drug Administration this fall and are proposed for use as monotherapy and as adjuncts to metformin as well as pioglitazone.
Mitsubishi Tanabe Pharma Corporation announced today that on July 3, 2017, Mitsubishi Tanabe Pharma received manufacturing and sales approval for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor TENELIA Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU Tablets (generic name: canagliflozin), from the Japanese Ministry of Health, Labour and Welfare.
MT-2412 is a combination drug consisting of TENELIA(R) Tablets, a selective DPP-4 inhibitor (generic name: teneligliptin), and CANAGLU(R) Tablets, an SGLT2 inhibitor (generic name: canagliflozin).
Of these, 40,736 had received metformin in combination with a sulfonylurea and 12,024 had received a combination of metformin and a DPP-4 inhibitor and were studied further.